Alebund Pharmaceuticals
Clinical trials sponsored by Alebund Pharmaceuticals, explained in plain language.
-
New drug AP301 aims to tame dangerous phosphate levels in dialysis patients
Disease control Recruiting nowThis phase 3 trial tests whether AP301 can safely lower high blood phosphate levels in people with end-stage kidney disease who are on dialysis. About 264 participants will receive either AP301 or a low-dose comparator for 8 weeks, then all receive AP301 for 24 weeks. The study m…
Phase: PHASE3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New pill for diabetic kidney disease enters early human testing
Disease control Recruiting nowThis early-stage study tests a new oral medication called AP303 in 18 adults with diabetic kidney disease. The main goals are to check the drug's safety and how the body handles it over two weeks. Participants will be randomly assigned to receive either AP303 or a placebo, and ne…
Phase: PHASE1 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:39 UTC